Cleared Traditional

K780894 - AIRFLOMETER

K780894 is the FDA 510(k) clearance for AIRFLOMETER by Glaxo Australia Ply. , Ltd.. It is a Class 2 Anesthesiology device (product code BZG) cleared through the Traditional 510(k) pathway after a 202-day FDA review.

K780894 · Glaxo Australia Ply. , Ltd. · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1978
Decision
202d
Days
Class 2
Risk

K780894 is an FDA 510(k) clearance for the AIRFLOMETER. Classified as Spirometer, Diagnostic (product code BZG), Class II - Special Controls.

Submitted by Glaxo Australia Ply. , Ltd. (Mchenry, US). The FDA issued a Cleared decision on December 14, 1978 after a review of 202 days - an extended review cycle.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.1840 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Anesthesiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Glaxo Australia Ply. , Ltd. devices

Submission Details

510(k) Number K780894 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 26, 1978
Decision Date December 14, 1978
Days to Decision 202 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
62d slower than avg
Panel avg: 140d · This submission: 202d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code BZG Spirometer, Diagnostic
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 868.1840
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Anesthesiology devices follow this clearance model.